EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CUE: Cue Biopharma Inc

24 Oct 25 15:59
LAST:

0.7851

CHANGE:
 0.00		OPEN:
0.7979		HIGH:
0.7997		ASK:
0.0000		VOLUME:
89.1K
CHG(%):
0.62		PREV:
0.7803		LOW:
0.7644		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 250.79790.79970.76440.785189.1K
23 Oct 250.76000.80100.76000.780361.1K
22 Oct 250.81000.84000.75670.7652159.5K
21 Oct 250.81000.84000.78000.8250142.5K
20 Oct 250.80000.83670.78620.8205255.2K
17 Oct 250.76000.80000.76000.796296.9K
16 Oct 250.78500.80000.76000.7901287.8K
15 Oct 250.80000.80000.78210.7850266.9K
14 Oct 250.81000.81970.78000.7974133.7K
13 Oct 250.84000.85680.80100.8151174.6K

COMPANY PROFILE

Name:Cue Biopharma Inc
About:Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:40 Guest Street, Boston, MA, United States, 02135
Website:https://www.cuebiopharma.com
CUSIP:22978P106
CIK:0001645460
ISIN:US22978P1066
FIGI:BBG00FVMPFN7
LEI:549300PBW78KZA33WC97

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.801.3%
MA10:0.801.4%
MA20:0.780.5%
MA50:0.771.4%
MA100:0.763.0%
MA200:0.8811.6%
STO9:26.60
STO14:15.75 
RSI14:55.77
WPR14:-81.20 
MTM14:0.03
ROC14:0.04 
ATR:0.07 
Week High:0.847.0%
Week Low:0.763.8%
Month High:0.9622.3%
Month Low:0.6811.6%
Year High:1.99153.4%
Year Low:0.5445.2%
Volatility:71.00